Transfusion requirements and clinical outcome in intensive care patients receiving continuous renal replacement therapy: comparison of prostacyclin vs. heparin prefilter administration

2010 ◽  
Vol 21 (5) ◽  
pp. 414-419 ◽  
Author(s):  
Nis A Windeløv ◽  
Sisse R Ostrowski ◽  
Anders Perner ◽  
Pär I Johansson
Keyword(s):  
Intensive Care ◽  
Renal Replacement Therapy ◽  
Clinical Outcome ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Intensive Care Patients ◽  
Transfusion Requirements

scholarly journals Pharmacokinetics of ciprofloxacin during continuous renal replacement therapy in intensive care patients – new assessment

2020 ◽  
Vol 52 (4) ◽  
pp. 267-273
Author(s):  
Dariusz Onichimowski ◽  
Joanna Wolska ◽  
Hubert Ziółkowski ◽  
Krzysztof Nosek ◽  
Jerzy Jaroszewski ◽  
...  
Keyword(s):  
Intensive Care ◽  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Intensive Care Patients

scholarly journals Citrate versus non-citrate anticoagulation in continuous renal replacement therapy: Results following a change in local critical care protocol

2016 ◽  
Vol 18 (1) ◽  
pp. 47-51
Author(s):  
Samina R Chowdhury ◽  
Tom Lawton ◽  
Aaqid Akram ◽  
Robert Collin ◽  
James Beck
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Regional Citrate Anticoagulation ◽  
Nursing Workload ◽  
Citrate Anticoagulation ◽  
Care Protocol ◽  
Transfusion Requirements

Continuous renal replacement therapy necessitates the use of anticoagulation. The anticoagulant of choice has traditionally been heparin. Emerging evidence has highlighted the deleterious effects of systemic heparin anticoagulation in the critically ill. Regional citrate anticoagulation has been used as an alternative in the setting of continuous renal replacement therapy. Our retrospective before-and-after cohort study aimed to ascertain if regional citrate anticoagulation is associated with any benefit in terms of circuit longevity, rates of complications, blood transfusion requirements and mortality, when introduced to a large general intensive care unit with a case mix of acute medical patients and acute and elective surgical patients. The switch to regional citrate anticoagulation for continuous renal replacement therapy in our intensive care unit has been associated with a dramatically longer circuit life, with major implications for cost savings in terms of reduced nursing workload. We hope to look at fiscal aspects of the change in protocol in greater depth.

Bioethical issues related to continuous renal replacement therapy in intensive care patients

2000 ◽  
Vol 26 (4) ◽  
pp. 407-415 ◽  
Author(s):  
N. Zamperetti ◽  
C. Ronco ◽  
A. Brendolan ◽  
R. Bellomo ◽  
G. Canato ◽  
...  
Keyword(s):  
Intensive Care ◽  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Intensive Care Patients ◽  
Bioethical Issues

scholarly journals Pharmacokinetics of meropenem in intensive care patients receiving continuous renal replacement therapy

Critical Care ◽  
10.1186/cc259 ◽  
1998 ◽  
Vol 2 (Suppl 1) ◽  
pp. P130
Author(s):  
LJ Giles ◽  
AC Barber ◽  
G Creed ◽  
B Ng ◽  
RJ Beale ◽  
...  
Keyword(s):  
Intensive Care ◽  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Intensive Care Patients
Sign in / Sign up

Export Citation Format

Share Document